Tertomotide is under clinical development by GemVax & KAEL and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tertomotide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GemVax & KAEL overview
GemVax & KAEL, is a pharmaceutical company. It develops and manufactures anti-cancer immunotherapeutic and peptide drugs to treat cancer. The company’s lead product candidate RIAVAX (GV1001), an immunotherapeutic peptide is used for the treatment of advanced or metastatic pancreatic cancer. GemVax & KAEL is also investigating GV1001 drug, against prostate cancer, benign prostate enlargement, Alzheimer’s disease and non-small cell lung carcinoma (NSCLC). The company is also involved in manufacture of pollution control equipment used in semiconductor manufacturing processes. The company offers coating resins and filters for producing semi-conductors and panel displays through its filter division. The Company distributes its products within domestic market and to overseas markets. GemVax & KAEL is headquartered in Dajeon, Korea.
For a complete picture of Tertomotide’s drug-specific PTSR and LoA scores, buy the report here.